Physician profile
Ann Shefferly Cothran
NPI 1962821827
$471.73
in general payments reported to CMS, 2019-2025
12 companies · $47.45 in 2025
The $47.45 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.53 · 2020: $56.09 · 2021: $46.05 · 2022: $68.70 · 2023: $97.51 · 2024: $100 · 2025: $47.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $101.32 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $93.60 | 2022-2024 | Azstarys |
| Cranial Technologies, INC | $70.86 | 2020-2022 | |
| Sanofi Pasteur INC. | $47.27 | 2019-2024 | |
| Sobi, INC | $33.21 | 2019-2023 | |
| Pfizer INC. | $27.24 | 2019-2020 | |
| Kaleo, INC. | $18.96 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.85 | 2024 | |
| Alk-Abello, INC | $18.07 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals Lp | $15.92 | 2023 | Flumist Quadrivalent |
| Seqirus USA INC | $13.24 | 2024 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Cothran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.